Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27770142 | 0.98 | CA12 (0.50) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL27805453 | 0.86 | HCAR2 (0.46) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL6305895 | 0.82 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9210765 | 0.81 | HCAR2 (0.52) | HCAR2LMNATSHRL3MBTL1RAB9A | |
| SCHEMBL27929947 | 0.80 | HCAR2 (0.46) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Isonicotinate SCHEMBL24935 | 0.79 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28214642 | 0.79 | CYP2C9 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1421640 | 0.79 | ALDH1A1 (0.58) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL11530768 | 0.78 | HCAR2 (0.44) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL14493579 | 0.77 | CA12 (0.56) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-115955916-A | Active compound combinations | 拜耳公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115697059-A | Active compound combinations | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| EP-3959214-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-6747039-B2 | INHIBITING CELL PROLIFERATION IN MAMMALS | ALBANY MOLECULAR RESEARCH, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030225069-A1 | Aza-benzothiopyranoindazoles with antitumor activity | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2003-12-04 | — | — | US | disclosed |
| US-20030212061-A1 | Aza-thioxanthenones with antitumor activity | ALBANY MOLECULAR RESEARCH, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003078647-A2 | AZA-BENZOTHIOPYRANOINDAZOLES WITH ANTITUMOR ACTIVITY | ALBANY MOLECULAR RESEARCH, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078646-A2 | AZA-THIOXANTHENONES WITH ANTITUMOR ACTIVITY | ALBANY MOLECULAR RESEARCH, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225069-A1 | Aza-benzothiopyranoindazoles with antitumor activity | AZI2, DUT, AADAC | HCAR2 1930/4885CA12 591/4885CA1 761/4885 |
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | HCAR2 153/4885CA12 4619/4885CA1 2882/4885 |
| US-20030212061-A1 | Aza-thioxanthenones with antitumor activity | AZI2, TPMT, MTAP | HCAR2 4505/4885CA12 2123/4885CA1 1548/4885 |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | HCAR2 3014/4885CA12 4558/4885CA1 4246/4885 |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | HCAR2 3790/4885CA12 3337/4885CA1 3271/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | HCAR2 3790/4885CA12 3337/4885CA1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.